

Appendix 2A

Application for quotation of +securities

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

If you are an entity incorporated outside Australia and you are seeking quotation of a new class of +securities other than CDIs, you will need to obtain and provide an International Securities Identification Number (ISIN) for that class. Further information on the requirement for the notification of an ISIN is available from the Create Online Forms page. ASX is unable to create the new ISIN for non-Australian issuers.

*Denotes minimum information required for first lodgement of this form, with exceptions provided in specific notes for certain questions. The balance of the information, where applicable, must be provided as soon as reasonably practicable by the entity.

Part 1 – Entity and announcement details

Question no	Question	Answer
1.1	*Name of entity We (the entity here named) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules. ¹	Anatara Lifesciences Limited
1.2	*Registration type and number <i>Please supply your ABN, ARSN, ARBN, ACN or another registration type and number (if you supply another registration type, please specify both the type of registration and the registration number).</i>	ACN 145 239 872 ABN 41 145 239 872
1.3	*ASX issuer code	ANR
1.4	*This announcement is <i>Tick whichever is applicable.</i>	☒ A new announcement ☐ An update/amendment to a previous announcement ☐ A cancellation of a previous announcement
1.4a	*Reason for update <i>Mandatory only if "Update" ticked in Q1.4 above. A reason must be provided for an update.</i>	N/A
1.4b	*Date of previous announcement to this update <i>Mandatory only if "Update" ticked in Q1.4 above.</i>	N/A
1.4c	*Reason for cancellation <i>Mandatory only if "Cancellation" ticked in Q1.4 above.</i>	N/A

¹ Appendix 2A of the Listing Rules includes a warranty that an offer of the securities for sale within 12 months after their issue will not require disclosure under section 707(3) or 1012C(6) of the Corporations Act. If the securities to be quoted have been issued by way of a pro rata offer, to give this warranty, you will generally need to have lodged a cleansing notice with ASX under section 708AA(2)(f) or 1012DAA(2)(f) of the Corporations Act within 24 hours before the securities are offered (see ASIC Regulatory Guide 189 *Disclosure relief for rights issues*). If in doubt, please consult your legal adviser.

1.4d	*Date of previous announcement to this cancellation <i>Mandatory only if "Cancellation" ticked in Q1.4 above.</i>	N/A
1.5	*Date of this announcement	4 December 2020

Part 2 – Type of issue

Question No.	Question	Answer
2.1	*The +securities to be quoted are: <i>Select whichever item is applicable.</i> <i>If you wish to apply for quotation of different types of issues of securities, please complete a separate Appendix 2A for each type of issue.</i>	☒ Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B ☐ Being issued under a +dividend or distribution plan ☐ Being issued as a result of options being exercised or other +convertible securities being converted ☐ Unquoted partly paid +securities that have been paid up and are now quoted fully paid +securities ☐ +Restricted securities where the escrow period has expired or is about to expire ☐ +Securities previously issued under an +employee incentive scheme where the restrictions on transfer have ceased or are about to cease ☐ +Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer ☐ Other
2.2a.1	*Date of Appendix 3B notifying the market of the proposed issue of +securities for which quotation is now being sought <i>Answer this question if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B"</i>	21 October 2020
2.2a.2	*Are there any further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B? <i>Answer this question if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B".</i>	No

2.2a.2.1	*Please provide details of the further issues of +securities yet to take place to complete the transaction(s) referred to in the Appendix 3B <i>Answer this question if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B" and your response to Q2.2a.2 is "Yes".</i> <i>Please provide details of the proposed dates and number of securities for the further issues. This may be the case, for example, if the Appendix 3B related to an accelerated pro rata offer with an institutional component being quoted on one date and a retail component being quoted on a later date.</i>	N/A
2.2b.1	*Date of Appendix 3A.1 lodged with ASX in relation to the underlying +dividend or distribution <i>Answer this question if your response to Q2.1 is "Being issued under a dividend or distribution plan".</i>	N/A
2.2b.2	*Does the +dividend or distribution plan meet the requirement of listing rule 7.2 exception 4 that it does not impose a limit on participation? <i>Answer this question if your response to Q2.1 is "Being issued under a dividend or distribution plan".</i> <i>Note: Exception 4 only applies where security holders are able to elect to receive all of their dividend or distribution as securities. For example, Exception 4 would not apply in the following circumstances: 1) The entity has specified a dollar limit on the level of participation e.g. security holders can only participate to a maximum value of \$x in respect of their entitlement, or 2) The entity has specified a maximum number of securities that can participate in the plan e.g. security holders can only receive securities in lieu of dividend payable for x number of securities.</i>	N/A
2.2c.1	Please state the number and type of options that were exercised or other +convertible securities that were converted (including their ASX security code) <i>Answer this question if your response to Q2.1 is "Being issued as a result of options being exercised or other convertible securities being converted".</i>	N/A
2.2c.2	And the date the options were exercised or other +convertible securities were converted <i>Answer this question if your response to Q2.1 is "Being issued as a result of options being exercised or other convertible securities being converted".</i> <i>Note: If this occurred over a range of dates, enter the date the last of the options was exercised or convertible securities was converted.</i>	N/A
2.2d.1	Please state the number and type of partly paid +securities (including their ASX security code) that were fully paid up <i>Answer this question if your response to Q2.1 is "Unquoted partly paid securities that have been paid up and are now quoted fully paid securities".</i>	N/A

2.2d.2	And the date the +securities were fully paid up <i>Answer this question if your response to Q2.1 is "Unquoted partly paid securities that have been paid up and are now quoted fully paid securities".</i> <i>Note: If this occurred over a range of dates, enter the date the last of the securities was fully paid up.</i>	N/A
2.2e.1	Please state the number and type of +restricted securities (including their ASX security code) where the escrow period has expired or is about to expire <i>Answer this question if your response to Q2.1 is "Restricted securities where the escrow period has expired or is about to expire".</i>	N/A
2.2e.2	And the date the escrow restrictions have ceased or will cease <i>Answer this question if your response to Q2.1 is "Restricted securities where the escrow period has expired or is about to expire".</i> <i>Note: If this occurred over a range of dates, enter the date the last of the escrow restrictions has ceased or will cease.</i>	N/A
2.2f.1	Please state the number and type of +securities (including their ASX security code) previously issued under the +employee incentive scheme where the restrictions on transfer have ceased or are about to cease <i>Answer this question if your response to Q2.1 is "Securities previously issued under an employee incentive scheme where the restrictions on transfer have ceased or are about to cease".</i>	N/A
2.2f.2	And the date the restrictions on transfer have ceased or will cease: <i>Answer this question if your response to Q2.1 is "Securities previously issued under an employee incentive scheme where the restrictions on transfer have ceased or are about to cease".</i> <i>Note: If this occurred over a range of dates, enter the date the last of the restrictions on transfer has ceased or will cease.</i>	N/A
2.2g.1	Please state the number and type of +securities (including their ASX security code) issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer <i>Answer this question if your response to Q2.1 is "Securities issued under an employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer".</i>	N/A

2.2g.2	*Please attach a document or provide details of a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms. <i>Answer this question if your response to Q2.1 is "Securities issued under an employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer".</i>	N/A					
2.2g.3	*Are any of these +securities being issued to +key management personnel (KMP) or an +associate <i>Answer this question if your response to Q2.1 is "Securities issued under an employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer".</i>	N/A					
2.2g.3.a	*Provide details of the recipients and the number of +securities issued to each of them. <i>Answer this question if your response to Q2.1 is "Securities issued under an employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer" and your response to Q2.2g.3 is "Yes". Repeat the detail in the table below for each KMP involved in the issue. If the securities are being issued to the KMP, repeat the name of the KMP or insert "Same" in "Name of registered holder". If the securities are being issued to an associate of a KMP, insert the name of the associate in "Name of registered holder".</i> <table border="1" data-bbox="339 969 1364 1066"> <thead> <tr> <th data-bbox="339 969 675 1014">Name of KMP</th><th data-bbox="675 969 1050 1014">Name of registered holder</th><th data-bbox="1050 969 1364 1014">Number of +securities</th></tr> </thead> <tbody> <tr> <td data-bbox="339 1014 675 1066">N/A</td><td data-bbox="675 1014 1050 1066"></td><td data-bbox="1050 1014 1364 1066"></td></tr> </tbody> </table>	Name of KMP	Name of registered holder	Number of +securities	N/A		
Name of KMP	Name of registered holder	Number of +securities					
N/A							
2.2h.1	*The purpose(s) for which the entity is issuing the +securities is: <i>Answer this question if your response to Q2.1 is "Other".</i> <i>You may select one or more of the items in the list.</i>	☒ To raise additional working capital ☐ To fund the retirement of debt ☐ To pay for the acquisition of an asset [provide details below] ☐ To pay for services rendered [provide details below] ☒ Other [provide details below] <i>Additional details:</i> The funds raised from the issue of the issue of the Shares will be used for clinical trials as well as general working capital requirements.					
2.2h.2	*Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including (if applicable) why the issue of the +securities has not been previously announced to the market in an Appendix 3B <i>You must answer this question if your response to Q2.1 is "Other". If there is no other information to provide, please answer "Not applicable" or "N/A".</i>	N/A					

2.2i	*Are these +securities being offered under a +disclosure document or +PDS? <i>Answer this question if your response to Q2.1 is any option other than "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B".</i>	No
2.2i.1	*Date of +disclosure document or +PDS? <i>Answer this question if your response to Q2.1 is any option other than "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B" and your response to Q2.2i is "Yes". Under the Corporations Act, the entity must apply for quotation of the securities within 7 days of the date of the disclosure document or PDS.</i>	N/A
2.3	*The +securities to be quoted are: <i>Tick whichever is applicable</i>	☒ Additional +securities in a class that is already quoted on ASX ("existing class") ☐ New +securities in a class that is not yet quoted on ASX ("new class")

Part 3A – number and type of +securities to be quoted (existing class or new class) where issue has previously been notified to ASX in an Appendix 3B

Answer the questions in this Part if your response to Q2.1 is "Being issued as part of a transaction or transactions previously announced to the market in an Appendix 3B" and your response to Q2.3 is "existing class" or "new class".

Question No.	Question	Answer
3A.1	*ASX security code & description	ANR: Ordinary Shares
3A.2	*Number of +securities to be quoted	3,666,666 fully paid Ordinary Shares

Part 4 – Issue details

Question No.	Question	Answer
4.1	*Have the +securities to be quoted been issued yet?	Yes
4.1a	*What was their date of issue? <i>Answer this question if your response to Q4.1 is "Yes".</i>	3 December 2020
4.1b	*What is their proposed date of issue? <i>Answer this question if your response to Q4.1 is "No".</i>	N/A
4.2	*Are the +securities to be quoted being issued for a cash consideration? <i>If the securities are being issued for nil cash consideration, answer this question "No".</i>	Yes
4.2a	*In what currency is the cash consideration being paid? <i>For example, if the consideration is being paid in Australian Dollars, state AUD. Answer this question if your response to Q4.2 is "Yes".</i>	AUD

4.2b	*What is the issue price per +security <i>Answer this question if your response to Q4.2 is "Yes" and by reference to the issue currency provided in your response to Q4.2a.</i> <i>Note: you cannot enter a nil amount here. If the securities are being issued for nil cash consideration, answer Q4.2 as "No" and complete Q4.2c and Q4.2d.</i>	\$0.15
4.2c	Please describe the consideration being provided for the +securities to be quoted <i>Answer this question if your response to Q4.2 is "No".</i>	N/A
4.2d	Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted <i>Answer this question if your response to Q4.2 is "No".</i>	N/A
4.3	Any other information the entity wishes to provide about the issue	Nil

Part 5 – Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise: <i>Note: the figures provided in the tables in sections 5.1 and 5.2 below are used to calculate the total market capitalisation of the entity published by ASX from time to time. Please make sure you include in the relevant table each class of securities issued by the entity.</i> <i>If you have quoted CHESS Depository Interests (CDIs) issued over your securities, include them in the table in section 5.1 and include in the table in section 5.2 any securities that do not have CDIs issued over them (and therefore are not quoted on ASX).</i> <i>Restricted securities should only be included in the table in section 5.1 if you are applying to have them quoted because the escrow period for the securities has expired or is about to expire. Otherwise include them in the table in section 5.2.</i>											
5.1	*Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities the subject of this application) <table border="1"> <thead> <tr> <th>ASX security code and description</th><th>Total number of +securities on issue</th></tr> </thead> <tbody> <tr> <td>ANR Ordinary Fully Paid</td><td>70,449,936</td></tr> <tr> <td> </td><td> </td></tr> <tr> <td> </td><td> </td></tr> <tr> <td> </td><td> </td></tr> </tbody> </table>	ASX security code and description	Total number of +securities on issue	ANR Ordinary Fully Paid	70,449,936						
ASX security code and description	Total number of +securities on issue										
ANR Ordinary Fully Paid	70,449,936										

5.2	*Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX): <table border="1"> <thead> <tr> <th data-bbox="341 271 954 309">ASX security code and description</th><th data-bbox="954 271 1428 309">Total number of +securities on issue</th></tr> </thead> <tbody> <tr> <td data-bbox="341 309 954 389">ANRAE: Options have an exercise price of \$1.45 per Option and expire on 14 December 2020</td><td data-bbox="954 309 1428 389">562,500 Options</td></tr> <tr> <td data-bbox="341 389 954 470">ANRAF: Options have an exercise price of \$1.70 per Option and expire on 23 September 2021</td><td data-bbox="954 389 1428 470">210,000 Options</td></tr> <tr> <td data-bbox="341 470 954 551">ANRAG: Options have an exercise price of \$2.27 per Option and expire on 17 November 2022</td><td data-bbox="954 470 1428 551">36,000 Options</td></tr> <tr> <td data-bbox="341 551 954 631">ANRAH: Options have an exercise price of \$1.45 per Option and expire on 14 December 2020</td><td data-bbox="954 551 1428 631">750,000 Options</td></tr> <tr> <td data-bbox="341 631 954 734">ANRAI: Options have an exercise price of \$0.7360 per Option and expire on 17 February 2024</td><td data-bbox="954 631 1428 734">600,000 Options</td></tr> <tr> <td data-bbox="341 734 954 949">Options (Broker Options) have an exercise price of \$0.25 per Option and expire on 3 December 2023 (the Director Options are the subject of the Appendix 3G lodged on the same date as this Appendix 2A)</td><td data-bbox="954 734 1428 949">1,500,000 Options</td></tr> <tr> <td data-bbox="341 949 954 1155">Options (Director, CEO & Comp Secretary Options) have an exercise price of \$0.2476 per Option and expire on 3 December 2022 (the Director, CEO & Comp Secretary Options are the subject of the Appendix 3G lodged on the same date as this Appendix 2A)</td><td data-bbox="954 949 1428 1155">617,704 Options</td></tr> <tr> <td data-bbox="341 1155 954 1205">Total Options</td><td data-bbox="954 1155 1428 1205">4,276,204</td></tr> <tr> <td data-bbox="341 1205 954 1285">Performance Rights: 780,985 expiring on 10 August 2023</td><td data-bbox="954 1205 1428 1285">780,985 Performance Rights</td></tr> </tbody> </table>	ASX security code and description	Total number of +securities on issue	ANRAE: Options have an exercise price of \$1.45 per Option and expire on 14 December 2020	562,500 Options	ANRAF: Options have an exercise price of \$1.70 per Option and expire on 23 September 2021	210,000 Options	ANRAG: Options have an exercise price of \$2.27 per Option and expire on 17 November 2022	36,000 Options	ANRAH: Options have an exercise price of \$1.45 per Option and expire on 14 December 2020	750,000 Options	ANRAI: Options have an exercise price of \$0.7360 per Option and expire on 17 February 2024	600,000 Options	Options (Broker Options) have an exercise price of \$0.25 per Option and expire on 3 December 2023 (the Director Options are the subject of the Appendix 3G lodged on the same date as this Appendix 2A)	1,500,000 Options	Options (Director, CEO & Comp Secretary Options) have an exercise price of \$0.2476 per Option and expire on 3 December 2022 (the Director, CEO & Comp Secretary Options are the subject of the Appendix 3G lodged on the same date as this Appendix 2A)	617,704 Options	Total Options	4,276,204	Performance Rights: 780,985 expiring on 10 August 2023	780,985 Performance Rights
ASX security code and description	Total number of +securities on issue																				
ANRAE: Options have an exercise price of \$1.45 per Option and expire on 14 December 2020	562,500 Options																				
ANRAF: Options have an exercise price of \$1.70 per Option and expire on 23 September 2021	210,000 Options																				
ANRAG: Options have an exercise price of \$2.27 per Option and expire on 17 November 2022	36,000 Options																				
ANRAH: Options have an exercise price of \$1.45 per Option and expire on 14 December 2020	750,000 Options																				
ANRAI: Options have an exercise price of \$0.7360 per Option and expire on 17 February 2024	600,000 Options																				
Options (Broker Options) have an exercise price of \$0.25 per Option and expire on 3 December 2023 (the Director Options are the subject of the Appendix 3G lodged on the same date as this Appendix 2A)	1,500,000 Options																				
Options (Director, CEO & Comp Secretary Options) have an exercise price of \$0.2476 per Option and expire on 3 December 2022 (the Director, CEO & Comp Secretary Options are the subject of the Appendix 3G lodged on the same date as this Appendix 2A)	617,704 Options																				
Total Options	4,276,204																				
Performance Rights: 780,985 expiring on 10 August 2023	780,985 Performance Rights																				